Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
219.8 CHF | -0.16% | -2.70% | -10.02% |
Apr. 17 | Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial | MT |
Apr. 17 | Roche: positive phase III results in MS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.02% | 194B | |
+28.71% | 676B | |
+24.34% | 554B | |
-7.41% | 349B | |
+14.39% | 318B | |
+7.81% | 291B | |
+3.21% | 210B | |
-0.29% | 204B | |
-11.74% | 144B | |
-7.84% | 142B |
- Stock Market
- Equities
- ROG Stock
- News Roche Holding AG
- Roche Agrees To Launch Cancer Drug Production In Kazakhstan